Dealmaker Securities
Fairness – Most popular
$58,915,995
Jupiter, Florida
Healthcare & Prescribed drugs
Cytonics, with a valuation of $58.9 million, is elevating funds on Dealmaker Securities. The corporate is a frontrunner in regenerative medication and has developed modern therapies for musculoskeletal illnesses like osteoarthritis. Cytonics has created an Autologous Platelet Built-in Focus system concentrating A2M from sufferers’ blood to deal with their very own broken joints. The corporate has a powerful IP portfolio with 22 issued US and worldwide patents. Gaetano Scuderi based Cytonics Company in July 2006. The present crowdfunding marketing campaign has a minimal goal of $25,000 and a most goal of $1.9 million. The marketing campaign proceeds will likely be used for GMP manufacturing of CYT-108, part 1 human medical trial, and dealing capital.
Abstract Revenue and Loss Assertion
|
Income |
$307,500 |
$591,056 |
|
COGS |
$2,205,358 |
$503,906 |
|
Tax |
$0 |
$0 |
|
|
||
|
|
||
|
Web Revenue |
$-22,544,189 |
$-995,850 |
Abstract Stability Sheet
|
Money |
$967,757 |
$537,354 |
|
Accounts Receivable |
$341,193 |
$283,676 |
|
Complete Belongings |
$1,756,758 |
$1,466,746 |
|
Quick-Time period Debt |
$554,929 |
$2,400,661 |
|
Lengthy-Time period Debt |
$0 |
$107,502 |
|
Complete Liabilities |
$554,929 |
$2,508,163 |
Financials as of: 01/03/2023
Increase Historical past
| Cytonics | 04/01/2023 | Dealmaker Securities | $58,915,995 | $0 | Fairness – Most popular |
Energetic |
RegCF |
| Cytonics | 10/14/2022 | SeedInvest | $58,915,996 | $2,633,766 | Fairness – Most popular |
Funded |
RegCF / RegD 506(c) |
| Cytonics | 04/30/2021 | SeedInvest | $46,701,000 | $4,667,638 | Fairness – Most popular |
Funded |
RegA+ |
| Cytonics | 05/18/2019 | SeedInvest | $32,400,000 | $494,344 | Convertible Be aware |
Funded |
RegCF / RegD 506(c) |
